Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Feb;38(2):326–329. doi: 10.1128/aac.38.2.326

In vivo interaction of ketoconazole and sucralfate in healthy volunteers.

P L Carver 1, R R Berardi 1, M J Knapp 1, J M Rider 1, C A Kauffman 1, S F Bradley 1, M Atassi 1
PMCID: PMC284448  PMID: 7910724

Abstract

Absorption of ketoconazole is impaired in subjects with an increased gastric pH due to administration of antacids, H2-receptor antagonists, proton pump inhibitors, or the presence of hypochlorhydria. Sucralfate could provide an attractive alternative in patients receiving ketoconazole who require therapy for acid-peptic disorders. Twelve healthy human volunteers were administered a single 400-mg oral dose of ketoconazole in each of three randomized treatment phases. In phase A, ketoconazole was administered orally with 240 ml of water. In phase B, ketoconazole and sucralfate (1.0 g) were administered simultaneously with 240 ml of water. In phase C, ketoconazole was administered with 240 ml of water 2 h after administration of sucralfate (1.0 g) orally with 240 ml of water. A 680-mg oral dose of glutamic acid hydrochloride was administered 10 min prior to and with each dose of ketoconazole, sucralfate, or ketoconazole plus sucralfate. Simultaneous administration of ketoconazole and sucralfate led to a significant reduction in the area under the concentration-time curve and maximal concentration of ketoconazole in serum (78.12 +/- 12.20 versus 59.32 +/- 13.61 micrograms.h/ml and 12.34 +/- 3.07 versus 8.92 +/- 2.57 micrograms/ml, respectively; P < 0.05). When ketoconazole was administered 2 h after sucralfate, the observed ketoconazole area under the concentration-time curve was not significantly decreased compared with that of ketoconazole alone. The time to maximal concentrations in serum and the ketoconazole elimination rate constant were not significantly different in any of the three treatment phases. In patients receiving concurrent administration of ketoconazole and sucralfate, doses should be separated by at least 2 h.

Full text

PDF
326

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baxter J. G., Brass C., Schentag J. J., Slaughter R. L. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. J Pharm Sci. 1986 May;75(5):443–447. doi: 10.1002/jps.2600750504. [DOI] [PubMed] [Google Scholar]
  2. Blum R. A., D'Andrea D. T., Florentino B. M., Wilton J. H., Hilligoss D. M., Gardner M. J., Henry E. B., Goldstein H., Schentag J. J. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991 May 1;114(9):755–757. doi: 10.7326/0003-4819-114-9-755. [DOI] [PubMed] [Google Scholar]
  3. Borella L. E., Seethaler K., Lippmann W. Sucralfate: antipeptic, antiulcer activities and antagonism of gastric emptying. Arzneimittelforschung. 1979;29(5):793–798. [PubMed] [Google Scholar]
  4. Carlson J. A., Mann H. J., Canafax D. M. Effect of pH on disintegration and dissolution of ketoconazole tablets. Am J Hosp Pharm. 1983 Aug;40(8):1334–1336. [PubMed] [Google Scholar]
  5. Daneshmend T. K., Warnock D. W., Turner A., Roberts C. J. Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother. 1981 Oct;8(4):299–304. doi: 10.1093/jac/8.4.299. [DOI] [PubMed] [Google Scholar]
  6. Dressman J. B., Berardi R. R., Dermentzoglou L. C., Russell T. L., Schmaltz S. P., Barnett J. L., Jarvenpaa K. M. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res. 1990 Jul;7(7):756–761. doi: 10.1023/a:1015827908309. [DOI] [PubMed] [Google Scholar]
  7. Guslandi M. Sucralfate and gastric bicarbonate. Pharmacology. 1985;31(5):298–300. doi: 10.1159/000138136. [DOI] [PubMed] [Google Scholar]
  8. Hall T. G., Cuddy P. G., Glass C. J., Melethil S. Effect of sucralfate on phenytoin bioavailability. Drug Intell Clin Pharm. 1986 Jul-Aug;20(7-8):607–611. doi: 10.1177/106002808602000726. [DOI] [PubMed] [Google Scholar]
  9. Hann I. M., Prentice H. G., Keaney M., Corringham R., Blacklock H. A., Fox J., Gascoigne E., Van Cutsem J. The pharmacokinetics of ketoconazole in severely immunocompromised patients. J Antimicrob Chemother. 1982 Dec;10(6):489–496. doi: 10.1093/jac/10.6.489. [DOI] [PubMed] [Google Scholar]
  10. Hikal A. H., Walker L. A., Ramachandran T. In vitro and in vivo interactions of furosemide and sucralfate. Pharm Res. 1987 Apr;4(2):171–172. doi: 10.1023/a:1016487507420. [DOI] [PubMed] [Google Scholar]
  11. Hoeschele J. D., Roy A. K., Pecoraro V. L., Carver P. L. In vitro analysis of the interaction between sucralfate and ketoconazole. Antimicrob Agents Chemother. 1994 Feb;38(2):319–325. doi: 10.1128/aac.38.2.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Knapp M. J., Berardi R. R., Dressman J. B., Rider J. M., Carver P. L. Modification of gastric pH with oral glutamic acid hydrochloride. Clin Pharm. 1991 Nov;10(11):866–869. [PubMed] [Google Scholar]
  13. Lachin J. M. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials. 1981 Jun;2(2):93–113. doi: 10.1016/0197-2456(81)90001-5. [DOI] [PubMed] [Google Scholar]
  14. Lake-Bakaar G., Tom W., Lake-Bakaar D., Gupta N., Beidas S., Elsakr M., Straus E. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1988 Sep 15;109(6):471–473. doi: 10.7326/0003-4819-109-6-471. [DOI] [PubMed] [Google Scholar]
  15. Lelawongs P., Barone J. A., Colaizzi J. L., Hsuan A. T., Mechlinski W., Legendre R., Guarnieri J. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm. 1988 Mar;7(3):228–235. [PubMed] [Google Scholar]
  16. Marano A. R., Caride V. J., Prokop E. K., Troncale F. J., McCallum R. W. Effect of sucralfate and an aluminum hydroxide gel on gastric emptying of solids and liquids. Clin Pharmacol Ther. 1985 Jun;37(6):629–632. doi: 10.1038/clpt.1985.101. [DOI] [PubMed] [Google Scholar]
  17. Nagashima R. Development and characteristics of sucralfate. J Clin Gastroenterol. 1981;3(Suppl 2):103–110. [PubMed] [Google Scholar]
  18. Nagashima R. Mechanisms of action of sucralfate. J Clin Gastroenterol. 1981;3(Suppl 2):117–127. [PubMed] [Google Scholar]
  19. Nagashima R., Yoshida N. Sucralfate, a basic aluminum salt of sucrose sulfate. I. Behaviors in gastroduodenal pH. Arzneimittelforschung. 1979;29(11):1668–1676. [PubMed] [Google Scholar]
  20. Petersen J. M., Caride V. J., Prokop E. K., Troncale F. J., McCallum R. W. Sucralfate delays gastric emptying of liquids and solids in duodenal ulcer patients. Int J Rad Appl Instrum B. 1989;16(4):389–395. doi: 10.1016/0883-2897(89)90106-2. [DOI] [PubMed] [Google Scholar]
  21. Piscitelli S. C., Goss T. F., Wilton J. H., D'Andrea D. T., Goldstein H., Schentag J. J. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991 Sep;35(9):1765–1771. doi: 10.1128/aac.35.9.1765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Smart H. L., Somerville K. W., Williams J., Richens A., Langman M. J. The effects of sucralfate upon phenytoin absorption in man. Br J Clin Pharmacol. 1985 Sep;20(3):238–240. doi: 10.1111/j.1365-2125.1985.tb05067.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Van Der Meer J. W., Keuning J. J., Scheijgrond H. W., Heykants J., Van Cutsem J., Brugmans J. The influence of gastric acidity on the bio-availability of ketoconazole. J Antimicrob Chemother. 1980 Jul;6(4):552–554. doi: 10.1093/jac/6.4.552. [DOI] [PubMed] [Google Scholar]
  24. Van Slooten A. D., Nix D. E., Wilton J. H., Love J. H., Spivey J. M., Goldstein H. R. Combined use of ciprofloxacin and sucralfate. DICP. 1991 Jun;25(6):578–582. doi: 10.1177/106002809102500601. [DOI] [PubMed] [Google Scholar]
  25. Van Tyle J. H. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984 Nov-Dec;4(6):343–373. doi: 10.1002/j.1875-9114.1984.tb03398.x. [DOI] [PubMed] [Google Scholar]
  26. Vu Van H., Piens M. A., Archimbaud E., Monier M. F., Guyotat D., Mojon M., Fiere D. Serum levels of ketoconazole in bone marrow transplanted patients. Nouv Rev Fr Hematol. 1983;25(4):241–244. [PubMed] [Google Scholar]
  27. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES